Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both.
Paul E PfefferNasloon AliRuth MurrayCharlotte UlrikTrung N TranJorge MasperoMatthew PetersGeorge C ChristoffMohsen SadatsafaviCarlos A Torres-DuqueAlan AltrajaLauri LehtimäkiNikolaos G PapadopoulosSundeep SalviRichard W CostelloBreda CushenEnrico HefflerTakashi IwanagaMona Al-AhmadDésirée Erlinda Larenas-LinnemannPiotr KunaJoão A FonsecaRiyad Al-LehebiChin Kook RheeLuis A Perez-de-LlanoDiahn-Warng Perng SteveBassam MahboubEileen WangCeline Yun Yi GohJuntao LyuAnthony NewellMarianna AlacquaAndrey S BelevskiyMohit BhutaniLeif BjermerUnnur BjornsdottirArnaud BourdinAnna von BulowJohn BusbyGiorgio Walter CanonicaBorja García CosioDel DorscheidMariana Muñoz-EsquerreJ Mark FitzGeraldEsther Garcia GilPeter G GibsonLiam G HeaneyMark HewOle HilbergFlavia HoyteAlexandra M NanzerMariko Siyue KohHsin-Kuo Ko BruceJae Ha LeeSverre LehmannClaudia Chaves LoureiroDóra LúðvíksdóttirAndrew N Menzies-GowPatrick MitchellAndriana I PapaioannouTodor A PopovCeleste M PorsbjergLaila SalamehConcetta SirenaCamille TailléChristian TaubeYuji TohdaMichael E WechslerDavid J PricePublished in: Allergy (2023)
In real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes, however anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.